2022年7期
刊物介紹
Cancer Biology & Medicine is a peer-reviewed open-access journal of Chinese Anti-cancer Association (CACA), which is the leading professional society of oncology in China. The journal quarterly provides innovative and significant information on biological basis of cancer, cancer microenvironment, translational cancer research, and all aspects of clinical cancer research. The journal also publishes significant perspectives on indigenous cancer types in China. The scope covers the following topics: ● Cancer epigenetics ● Cancer stem cell ● Improved in vivo and in vitro cancer models ● Cancer prevention and epidemiology ● Biomarkers for predicting drug response ● Mechanism of drug sensitivity and resistance ● New approaches for cancer detection and diagnosis ● Oncology clinical trials ● Targeted therapy ● Multidisciplinary treatment for cancer Author benefits: ● Easy online submission via Editorial Manager ● Efficient and professional peer-review by expert referees from around the world ● Rapid pre-print online publication ● No charge for publication and Open Access ● International visibility - the journal is available free online
Cancer Biology & Medicine
ORIGINALARTICLE
- ANTP-SMACN7 fusion peptide alone induced high linear energy transfer irradiation radiosensitization in non-small cell lung cancer cell lines
- Dual-targeted lung cancer therapy via inhalation delivery of UCNP-siRNA-AS1411 nanocages
- Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma:a prospective phase II trial
- SY-1530, a highly selective BTK inhibitor, effectively treats B-cell malignancies by blocking B-cell activation
- IL13Rα1 prevents a castration resistant phenotype of prostate cancer by targeting hexokinase 2 for ubiquitin-mediated degradation
- Identification of hub genes and their novel diagnostic and prognostic significance in pancreatic adenocarcinoma
- Feasibility of sentinel lymph node biopsy omission after integration of 18F-FDG dedicated lymph node PET in early breast cancer: a prospective phase II trial
- Bilirubin inhibits the anticancer activity of sorafenib by blocking MCL-1 degradation in hepatocellular carcinoma cells
- Microwave ablation vs. surgical resection for treatment na?ve hepatocellular carcinoma within the Milan criteria:a follow-up of at least 5 years